"Redefining Leishmaniasis Therapy: Innovations in Drug Discovery and Vaccine Design". (PubMed, Microb Pathog) - Sep 29, 2026 - "Promising candidates like LXE408, GSK3494245, DDD853651, PF-429242 and the cytochrome bc1 inhibitor DNDI-6174 have demonstrated promising preclinical or early clinical potential...While genetically attenuated strains like LmCen-/- have proven significant protection in experimental and veterinary contexts, candidates including LEISH-F1, LEISH-F3+GLA-SE, and ChAd63-KH, Neoleish, GH18-cpLeish and CpG-adjuvant virus-like particle vaccine have demonstrated safety and immunogenicity in early clinical studies. However, vaccine development is still hampered by issues like antigenic diversity, immune evasion by the parasite, and the absence of trustworthy correlates of protection. Overall, combining cutting-edge drug discovery technology with innovative vaccine platforms offers promising opportunities for developing effective therapeutic and preventive strategies for leishmaniasis."
Journal • Review • Infectious Disease
|
|
Ravinder Sharma; Shailesh Sharma; Swati Pal
|